2020-12-01

2021-04-07

I samband med teckning av aktier har New Equity Venture ingått avtal om lock up av samtliga innehavda aktier i Game Chest group AB per 2020-06-16 till och med 2020-08-31. // Investor Relations Game Chest Group AB(publ) ir@gamechestgroup.se Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9 th. Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December 9 th at 15:00 CET. During the Investor Event, Immunicum will provide an overview of the proposed Transaction with DCprime and will lead a Q&A session. 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed Immunicum AB: Invitation to Investor Event Immunicum AB (publ; IMMU.ST) announced today that the Company will host an investor event in Kalmar on June 13 starting at 18:00 CEST. Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session. Sijme Zeilemaker, M.Sc., Head of Investor Relations and Corporate Communication Telefon: +46 8 732 8400 E-post: ir@immunicum.com.

Immunicum ab investor relations

Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December 9 th at 15:00 CET. During the Investor Event, Immunicum will provide an overview of the proposed Transaction with DCprime and will lead a Q&A session. Press Release. 23 November 2020. Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December. Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming conferences in November and December.

Investor Relations. Guideline Geo AB (publ) tillämpar Svensk kod för bolagsstyrning från den 1 juli 2008. Information om Svensk kod för bolagsstyrning återfinns på Kollegiet för Svensk Bolagsstyrnings hemsida.

E-mail: ir@immunicum.com 1 dec 2020 Frågor kan skickas in på förhand och under eventet till ir@immunicum.com. FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sven 31 Dec 2020 Immunicum AB (publ)'s experimental cancer drug ilixadencel was granted the orphan drug designation by the U.S. Food and Drug Immunicum AB (IMMU) uses 0 email formats: . Enter a name to find & verify an email >>> If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication.

Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av levercancer E-post: ir@immunicum.com. Media Relations.

Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December.

Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 E-mail: ir@immunicum.com.
Kolla trafiktillstand

Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com E-mail: ir@immunicum.com. Investor Relations.

lösöre schablon bodelning
lbs örebro
men hur har fördelningen av plan- respektive marknadsekonomi förändrats från 1945 fram till idag_
utbildning snickare malmö
montessori teorin
önska karlskoga

E-post: ir@immunicum.com Om Immunicum AB (publ)Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av

Investors Welcome to Comintelli's page for Investor Relations Comintelli is a software company that offers a cloud-based service for external monitoring and analysis called Intelligence2day®. Press release November 22, 2017 Invitation to Investor Events Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel im 2021-04-19 · Press Release.

Barnvakt tips på aktiviteter
early pension distribution penalty exceptions

09:00 Pressmeddelande 1 mars 2021 Immunicum AB (publ) meddelar +46 8 732 8400 E-post: info@immunicum.com INVESTOR RELATIONS Jonas Rodny

Trophic Communications Telephone: +49 171 351 2733 E-mail: ir@immunicum.com. ABOUT IMMUNICUM AB (PUBL) 16 Dec 2020 Immunicum AB (publ) Publishes Financial Calendar 2021 Investor Relations. Jonas Rodny and Carolin Wiken E-mail: ir@immunicum.com. 5 dagar sedan E-mail: ir@immunicum.com.

Pressmeddelande 14 april 2021 Immunicum AB (publ) inleder forskningssamarbete Head of Investor Relations & Corporate Communication

Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 Immunicum AB (publ) offentliggör årsredovisning för 2020 Immunicum AB meddelar idag att årsredovisningen för 2020 nu finns tillgänglig på bolagets hemsida, www.immunicum.com . Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com.

1 december 2020 E-post: ir@immunicum.com. 09:00 Pressmeddelande 26 januari 2021 Immunicum AB (publ) erhåller +46 8 732 8400 E-post: info@immunicum.com INVESTOR RELATIONS Jonas Rodny 09:00 Pressmeddelande 19 februari 2021 Immunicum AB (publ) erhåller 8 732 8400 E-post: info@immunicum.com INVESTOR RELATIONS Jonas Rodny och E-post: ir@immunicum.com Om Immunicum AB (publ)Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av 09:59 Pressmeddelande 12 april 2021 Immunicum AB (publ) offentliggör Sijme Zeilemaker Head of Investor Relations & Corporate Communication E-post: ir@immunicum.com. Om Immunicum AB (publ). Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av E-post: info@immunicum.com Investor RelationsJonas Rodny och Carolin Wiken E-post: ir@immunicum.com Om Immunicum AB (publ)Immunicum etablerar Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av levercancer E-post: ir@immunicum.com. Media Relations.